SITABASE MER
Description
- Contains Sitagliptin 100 mg and Metformin 500 mg (Sustained Release).
- Sitagliptin increases insulin secretion and decreases glucagon in a glucose-dependent manner.
- Metformin SR reduces liver glucose output and improves insulin sensitivity with fewer GI side effects.
- Provides effective control of both fasting and post-meal blood glucose levels.
- Lower risk of hypoglycemia compared to many other antidiabetic agents.
- Sustained-release formulation enhances tolerability and patient compliance.
- Suitable for use alone or in combination with other diabetes medications under medical supervision.
Composition
SITAGLIPTIN-100 MG, METFORMINE-500 MG (SR)
Benefits
SITABASE MER offers dual-action glucose-lowering benefits by combining the complementary mechanisms of Sitagliptin and sustained-release Metformin. This combination helps achieve better control of fasting and postprandial blood sugar levels with a lower risk of hypoglycemia. The sustained-release Metformin improves patient tolerance by reducing gastrointestinal discomfort often associated with immediate-release formulations. Together, they support improved metabolic health, aid in weight management, and enhance patient adherence through convenient once- or twice-daily dosing.
Introduction
SITABASE MER is a fixed-dose combination tablet containing Sitagliptin 100 mg and Metformin 500 mg (Sustained Release), formulated to effectively manage blood glucose levels in adults with type 2 diabetes mellitus. Sitagliptin, a DPP-4 inhibitor, enhances incretin hormone levels to stimulate insulin secretion and inhibit glucagon release, while Metformin SR reduces hepatic glucose production and improves peripheral insulin sensitivity. The sustained-release formulation of Metformin ensures gradual absorption, minimizing gastrointestinal side effects and providing consistent glycemic control throughout the day.
